LP 98
Alternative Names: LP-98Latest Information Update: 08 Oct 2024
At a glance
- Originator Shanxi Kangbao Biological Product
- Class Antiretrovirals; Lipopeptides
- Mechanism of Action HIV fusion inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II HIV infections
Most Recent Events
- 02 Sep 2024 Phase-I/II clinical trials in HIV infections (Treatment-naive) in China (SC) (NCT06560489)
- 19 Aug 2024 Shanxi Kangbao Biological plans a phase I/II trial for HIV infections in an undisclosed location (SC) (NCT06560489)
- 12 Apr 2024 Shanxi Kangbao Biological completes a phase I trial in HIV infections (In volunteers, In adults) in China (SC) (IV)(NCT05933824)